Replies to post #248102 on Biotech Values

[DewDiligence]

Addendum—ABT’s FreeStyle Libre is now selling at an annualized rate of $5.2B(!), making it the biggest-selling medical device, ever, from any company.

[DewDiligence]

ABT is_working_on_a 15-minute, hand-held diagnostic_for TBI*, using_blood_from_a finger_prick. (Source: today’s 2Q23 CC.)

Existing concussion protocols leave a lot to be desired. Managers of sports teams from professional to grade school are going to want this device.

*Traumatic Brain Injury.

[DewDiligence]

ABT inks deal to_sell biosimilars in emerging markets:

https://www.prnewswire.com/news-releases/abbott-broadens-access-to-cutting-edge-biosimilars-in-key-emerging-markets-301932956.html

In emerging markets, consumers care greatly about the reputation of the manufacturer, which is why so-called “branded generics” can be a high-margin business for a company such as ABT. Biosimilars are a natural fit for ABT’s existing business in off-patent small-molecule drugs, which comprises 13% of ABT’s overall corporate sales (#msg-172393746).

[DewDiligence]

ABT +4% on 3Q23 beat-and-raise:

#msg-173045453
#msg-173045466